AMSTERDAM – Europe's famously fragmented system – or systems – for pricing and reimbursement will lose a few rough edges in the years ahead, as coordinated clinical assessment of product dossiers becomes the norm for all therapeutic products that are currently subject to the EMA's centralized market authorization process.